Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Fifth Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020

Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ:JAGX) announced a fifth amendment to its accounts receivable agreement with Oasis Capital, LLC, allowing the purchase of additional accounts receivable totaling $3,810,587.04 from October 13 to December 2, 2020. This financing represents a strategic move to secure non-dilutive capital as the company sees growing sales of its Mytesi drug product.

Oasis will pay $1,619,499.49 for these receivables and charge a 5.45% fee. This indicates an increase in the financing percentage compared to previous agreements.

Positive

• Secured additional non-dilutive capital of $3,810,587.04.
• Growing sales of Mytesi indicate positive market demand.
• Terms of financing show improved conditions compared to earlier agreements.

Negative

• Increased fee percentage at 5.45% compared to previous purchases.

The Sixth Tranche Accounts Receivable has a gross value of $3,810,587.04, representing customer billings over a 51-day period

SAN FRANCISCO, CA / ACCESSWIRE / December 4, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., (collectively, the "Company") have jointly entered into a fifth amendment to the accounts receivable purchase agreement with Oasis Capital, LLC ("Oasis"), dated May 12, 2020, pursuant to which Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi^® drug product to Cardinal Health for the period of October 13, 2020 through December 2, 2020 (the "Sixth Tranche Accounts Receivable"). The Sixth Tranche Accounts Receivable has a gross value of $3,810,587.04, representing customer billings over a 51-day period.

"We are happy to enter into this additional amendment with Oasis. Based on the success of the previous five tranches of accounts receivable financing and the strength of our growing sales of Mytesi, we have been able to further our strategy of bringing in non-dilutive capital and striving to become a sustainable, cash flow positive commercial business," said Lisa Conte, Jaguar's president and CEO.

Per the terms of the agreement, Oasis will receive a fee of 5.45% (the "Fee") of the $3,810,587.04 Sixth Tranche Accounts Receivable following their purchase of the Sixth Tranche Accounts Receivable for $1,619,499.49, an increased percentage of the gross accounts receivable compared to the April 2020 purchase (the "Purchase Price"). As with prior accounts receivable sales to Oasis, Oasis will return to the Company any amount that exceeds the sum of the Purchase Price and the Fee. As with all Mytesi gross sales, the Sixth Tranche Accounts Receivable will be reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical trends to determine net sales.

Under the amendment, Oasis is entitled to a one-time transaction fee of $5,000.

About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi^® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

About Mytesi^®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View source version on accesswire.com:
https://www.accesswire.com/619435/Jaguar-Health-and-its-Subsidiary-Napo-Pharmaceuticals-Enter-into-Fifth-Amendment-to-the-Accounts-Receivable-Purchase-Agreement-with-Oasis-Capital-LLC-Dated-May-12-2020

FAQ

What is the value of the Sixth Tranche Accounts Receivable for JAGX?

The Sixth Tranche Accounts Receivable has a gross value of $3,810,587.04.

What percentage fee is Oasis Capital charging for the Sixth Tranche Accounts Receivable?

Oasis Capital is charging a fee of 5.45%.

How much did Oasis Capital pay for the Sixth Tranche Accounts Receivable?

Oasis Capital paid $1,619,499.49 for the Sixth Tranche Accounts Receivable.

What is the significance of the accounts receivable purchase agreement for JAGX?

The agreement provides non-dilutive capital and supports Jaguar's strategy to achieve sustainable, cash flow positive operations.

What product is related to the accounts receivable for JAGX?

The accounts receivable are related to the sales of Mytesi, Jaguar's drug product.